Table 1, Selection Criteria - Sequencing of Pharmacological Management of Crohn’s Disease and Ulcerative Colitis: A Review of Guidelines

Population	Adults and pediatric patients with moderate to severe Crohn’s disease or Ulcerative Colitis
Intervention	Sequencing of pharmacological therapy options vedolizumab, adalimubab, infliximab, golimumab, ustekinumab (biologics) are of primary interest, relative to conventional options like corticosteroids and immunosuppressants
Comparator	Not applicable
Outcomes	Guidelines regarding the early use of biologics (as first-line therapy)
Study Designs	Evidence-based guidelines

From: Sequencing of Pharmacological Management of Crohn’s Disease and Ulcerative Colitis: A Review of Guidelines

Cover of Sequencing of Pharmacological Management of Crohn’s Disease and Ulcerative Colitis: A Review of Guidelines

Sequencing of Pharmacological Management of Crohn’s Disease and Ulcerative Colitis: A Review of Guidelines [Internet].

Ho C, Argáez C.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jan 31.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Table 1Selection Criteria